Fevertree Drinks (FEVR) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
8 Jul, 2026Executive summary
Achieved 4% constant currency revenue growth and 66% increase in Adjusted EBITDA, driven by margin recovery, working capital optimization, and strong brand momentum.
Entered a transformational partnership with Molson Coors in the U.S., providing guaranteed profits, lower working capital needs, and significant growth potential.
Expanded share buyback program to GBP 100 million for the year, reflecting strong cash generation and confidence in future prospects.
Continued to gain market share in key regions, with double-digit U.S. growth and strong performance in Australia and Canada.
Maintains #1 premium mixer brand status globally, with strong innovation and distribution capabilities.
Financial highlights
FY24 brand revenue reached £364.0m, up 4% at constant currency; total group revenue was £368.5m, up 3% at constant currency.
Adjusted EBITDA increased 66% to £50.7m (margin 13.7%, +530bps YoY); operating profit up 57% to £32.8m.
Gross margin improved to 37.5% (+540bps YoY) due to lower glass and freight costs, pricing actions, and operational efficiencies.
Operating cash flow conversion reached 150%, with net cash up 60% to £96.0m.
Final dividend recommended to increase by 2% to 16.97p per share.
Outlook and guidance
2025 guidance: low single-digit group revenue growth, with short-term EBITDA impact due to US transition.
2026: double-digit group revenue and EBITDA growth expected as US marketing spend normalizes.
From 2027, uplift in group revenue and EBITDA anticipated as Molson Coors partnership benefits are fully realized, underpinned by guaranteed royalty fees.
Ongoing focus on margin improvement, procurement efficiency, and technical optimization.
US profit trajectory de-risked by guaranteed profit element from Molson Coors for 2026–2030.
Latest events from Fevertree Drinks
- Revenue up 4% in 2025, with U.S. partnership and diversification fueling future growth.FEVR
H2 202524 Mar 2026 - FY25 revenue and EBITDA to surpass expectations, with robust US and global growth.FEVR
Trading update29 Jan 2026 - 79% EBITDA growth and 520bps margin gain in H1, with strong US and global share gains.FEVR
H1 202420 Jan 2026 - Molson Coors takes 8.5% stake, US operations, and guarantees royalties for accelerated growth.FEVR
Partnership9 Jan 2026 - US partnership, diversification, and strong cash drive growth; outlook and buybacks positive.FEVR
H1 202512 Sep 2025 - Fever-Tree delivers market share gains and reaffirms full year outlook with global growth.FEVR
Trading Update13 Jun 2025 - Strong US growth, UK leadership, and robust capital returns mark Fever-Tree's 2025 update.FEVR
Trading Update9 Jun 2025